Ashley Classen, DO
Interventional Pain Medicine · Fort Worth, TXNPI 1629071733
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 41.2% of the total. Reporting peaked in 2019 at $12,995 and has fallen 90.6% since, to $1,228 in 2025. Among interventional pain medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $90.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Genesys Orthopedics Systems, L.L.C.$9K
- Nevro Corp.$4K
- Spinal Simplicity, LLC$2K
- Saluda Medical Americas, Inc.$2K
- Southern Spine, LLC$2K
- plus $7K from 28 others
Across 1 payment — averaging $820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$820
What the payments were for
- Consulting fees$8,70020%
- Speaking & faculty fees$14,35833%
- Travel & lodging$5,46213%
- Food & beverage$14,37733%
- Education$210%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 166 | $17,703 |
| Genesys Orthopedics Systems, L.L.C. | 11 | $8,513 |
| Nevro Corp. | 58 | $3,674 |
| Spinal Simplicity, LLC | 30 | $2,081 |
| Saluda Medical Americas, Inc. | 9 | $2,073 |
| Southern Spine, LLC | 1 | $1,700 |
| Vertiflex, Inc. | 46 | $1,640 |
| Boston Scientific | 33 | $1,113 |
| Nalu Medical, Inc. | 22 | $795 |
| Abbott | 15 | $662 |
| Vertos Medical, Inc. | 5 | $475 |
| Globus Medical | 8 | $402 |
| Amgen | 11 | $356 |
| Painteq LLC | 8 | $342 |
| SPR Therapeutics, Inc | 6 | $267 |
| Vyaire Medical, Inc. | 2 | $150 |
| Relievant Medsystems, Inc. | 2 | $130 |
| Pfizer | 7 | $112 |
| Vertex | 4 | $101 |
| Tersera Therapeutics LLC | 4 | $100 |
| MML US, Inc. | 2 | $87 |
| Lundbeck LLC | 4 | $81 |
| GRT US Holding, Inc. | 2 | $71 |
| Si-bone, Inc. | 3 | $63 |
| Forte Bio-pharma LLC | 2 | $47 |
| Hikma Pharmaceuticals USA | 2 | $39 |
| Foundation Fusion Solutions, LLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Biogen | 1 | $16 |
| Orexo US, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Curonix LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SACROILIAC JOINT FUSION SYSTEM$16,836
- RESTORE$4,960
- INTELLIS$3,600
- INTELLIS ADAPTIVESTIM$3,272
- SYNCHROMED$3,098
- Evoke SCS$2,031
- Senza Spinal Cord Stimulation System$1,238
- Superion ISS$1,183
- HA MINUTEMAN G3-R$1,168
- Senza$821
- Omnia$573
- Intracept$459
- mild Device Kit$259
- Nalu Neurostimulation System$244
- VANTA ADAPTIVESTIM$223
- Proclaim Family of SCS IPGs$206
- ADAPTIVESTIM$154
- Vanta$146
- S-Series SCS Leads$140
- SUPERION$116
How this compares
$42,933 in reported general payments places this provider in the 90th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ajovy SyringeFremanezumab-Vfrm | 12 | $8,238 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 74 | $7,097 |
| Buprenorphine | 29 | $3,763 |
| Celecoxib | 39 | $1,586 |
| Gabapentin | 113 | $1,557 |
| Duloxetine Hcl | 106 | $1,532 |
| Methocarbamol | 106 | $1,449 |
| Naloxone Hcl | 19 | $1,336 |
| Pregabalin | 56 | $885 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $730 |
| Cefadroxil | 51 | $385 |
| Tizanidine Hcl | 45 | $373 |
| Clindamycin Hcl | 19 | $260 |
| Hydroxyzine Hcl | 11 | $256 |
| Tramadol Hcl | 40 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine | $39 | $10,860103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Fort Worth
- Timothy RatinoFort Worth$139K
- Robert MenziesFort Worth$85K
- Thomas RatinoFort Worth$20K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.